General Information


We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on our proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our “off-the-shelf” technologies, VaxWave and TheraT, to elicit directly within patients a powerful and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defenses against infectious diseases and cancers. We believe that our technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by eliciting killer T cell response levels previously not achieved by other published immunotherapy approaches. Our lead infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Our lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers.

Employees: 60
Founded: 2011
Contact Information
Address 350 Fifth Avenue, 72nd Floor, New York, NY 10118, US
Phone Number +43 1 890 63 60
Web Address http://www.hookipapharma.com
View Prospectus: HOOKIPA Pharma
Financial Information
Market Cap $302.2mil
Revenues $7.6 mil (last 12 months)
Net Income $-16.2 mil (last 12 months)
IPO Profile
Symbol HOOK
Exchange NASDAQ
Shares (millions): 6.0
Price range $14.00 - $14.00
Est. $ Volume $84.0 mil
Manager / Joint Managers BofA Securities/ SVB Leerink/ RBC Capital Markets
CO-Managers Kempen & Co.
Expected To Trade: 4/18/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change